This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1.
Confirming post #30 from a second method, which matters more than confirming it from a second person.
Stockpiling in response to a shortage worsens it, which is true and is a poor argument to make to somebody who has run out.
This is the sort of thing the wiki should carry and currently does not.
The published shortage register maintained by the national regulator is the authoritative source here, and it is updated far more often than any thread.
Reading it back, the second half matters more than the first.
Managing an unplanned gap: if a shortage causes a gap in treatment, the questions are how long the gap will be and how that affects your condition. Discussing with your clinician is prudent if the gap is weeks or longer.
Post #32 describes the usual case. This is about the unusual one.
Tracking a shortage is one of those subjects where the general answer and the answer for a specific case diverge, and the thread will go in circles until someone says which one is being asked for.
Post #34 is right about the mechanism and I think understates the practical bit.
Anyone reporting availability should say the region and the date, because both determine whether the report is usable.
I would hold that lightly until someone with a larger sample weighs in.
Coming back to post #32, because the follow-up matters more than the original answer.
Pharmacy-level availability varies enormously during a shortage, so two honest accounts from the same city can be opposite.
Two sources, same conclusion, and I could not rule out that one copied the other.
International supply chains: a shortage in one country does not mean shortage in another. That is why ordering from multiple suppliers before a shortage gets bad is prudent if you can.
Regional differences during a shortage are large, and a supply position in one country says nothing about another.
Post #36 put the caveat in the right place and I want to underline it.
Reports that a pharmacy has stock are the least durable information on the site and are still worth posting with a date.
Agreed, and I will stop repeating the version of this I had been repeating.
Where I part company with post #42, and it is a narrow parting.
Switching presentation or strength during a shortage is a prescribing decision rather than a substitution anybody should improvise.
That is the version I use. It may not be the version that is correct.
Where a shortage forces a gap, the pharmacokinetics mean a missed week is a perturbation rather than a reset, which is worth knowing.
The most useful reply I ever got about tracking a shortage was a request to state my units. It sounds like pedantry and it has saved me twice.
Confirming post #45 from a second method, which matters more than confirming it from a second person.
Planning around a known shortage window is easier than reacting to one, and the notices give advance warning more often than people expect.
The answer changed when I changed how I was measuring, which was informative.
Supply interruptions: official shortage notices are published by regulatory agencies. That is the correct primary source rather than pharmacy rumors or forum discussion.
Manufacturer allocation decisions during a shortage are commercial and are rarely explained, which is frustrating and is not evidence of anything.
That matches what I was told, which is not the same as knowing it.
Stockpiling in response to a shortage worsens it, which is true and is a poor argument to make to somebody who has run out.
Not the whole picture, but the part of it I can speak to.
Post #50 put the caveat in the right place and I want to underline it.
Managing an unplanned gap: if a shortage causes a gap in treatment, the questions are how long the gap will be and how that affects your condition. Discussing with your clinician is prudent if the gap is weeks or longer.
Tracking a shortage is worth one more sentence than it usually gets, and the sentence is the one about how the number was arrived at.
Post #56 is the version of this I will quote in future. One addition.
A shortage of one presentation is not a shortage of all of them, and the published notices are specific about which.
Post #56 is right about the mechanism and I think understates the practical bit.
Anyone reporting availability should say the region and the date, because both determine whether the report is usable.
One more caveat and then I will stop qualifying: the sample selected itself.
Small methodological point on tracking a shortage: repeating a measurement is cheap and resolves most of what is being argued about here at no cost to anyone.